Wormwood for Crohn's Disease: What the Evidence Shows

Wormwood - the bitter herb that gave absinthe its name - is one of a small handful of herbal supplements that has actually been tested in clinical trials specifically enrolling Crohn's disease patients. If you have come across claims that Artemisia absinthium can lower TNF-alpha and put Crohn's into remission, you are not reading fiction: two small German trials did report those outcomes. But the distance between "two pilot studies totaling about 60 patients" and "a proven treatment" is enormous. In this guide, we walk through both trials in plain language, lay out the real safety concerns around thujone, and help you figure out what to bring to your next GI appointment.

Key Takeaways

• Two small German trials (40 and 20 patients) found that wormwood reduced TNF-alpha levels and CDAI scores in Crohn's disease patients, with symptom remission reported in 8 of 10 patients versus 2 of 10 controls in the 2010 study (1, 2).
• The 2007 trial suggested a steroid-sparing effect when wormwood was added alongside a steroid taper, but the blend included other herbs and the sample was small (1).
• Wormwood contains thujone, a GABA-A receptor antagonist that can trigger convulsions, sleeplessness, and hallucinations at high or prolonged doses - the essential oil should never be taken internally (4).
• No major gastroenterology society recommends wormwood for Crohn's disease, and the total evidence base comes from a single research group with no independent replication in over a decade (3).
• Always bring the specific product, brand, and dose to your gastroenterologist before trying wormwood, and never use it to replace a prescribed biologic or immunomodulator.

What Is Wormwood and Why Are Crohn's Patients Curious About It?

Artemisia absinthium is a silvery-green perennial herb native to Europe, Asia, and North Africa. For centuries, herbalists have used its intensely bitter leaves and flowering tops in digestive tonics, vermifuges (anti-parasite preparations), and the infamous spirit absinthe. If you have ever tasted a particularly bitter digestif in a European restaurant, there is a decent chance wormwood was involved.

The Plant and Its Traditional Digestive Use

The bitterness of wormwood comes from compounds called sesquiterpene lactones - among them absinthin and anabsinthin - along with flavonoids and volatile oils (4). Traditional medicine attributed its digestive benefits to the simple fact that intensely bitter substances stimulate gastric secretion. Modern researchers, however, became interested in wormwood for a different reason: some of its chemical constituents appeared to modulate immune signaling pathways, including tumor necrosis factor-alpha (TNF-alpha), one of the central inflammatory molecules in Crohn's disease.

Why Researchers Investigated It for Crohn's Disease

The connection between wormwood and Crohn's research is more specific than you might expect. Two groups of investigators based in Germany - where herbal medicine has a long tradition within mainstream healthcare - designed clinical trials specifically testing wormwood in diagnosed Crohn's disease patients. This is unusual in herbal research, where most studies are conducted in general IBD, ulcerative colitis, or irritable bowel syndrome populations. The fact that these trials targeted Crohn's disease specifically is part of why wormwood for Crohn's disease attracts so much patient attention online. If you have been exploring other herbal supplements with anti-inflammatory evidence, our guide to Boswellia serrata for Crohn's disease offers a useful comparison.

The 2007 Steroid-Sparing Placebo-Controlled Trial

The first major trial to test wormwood in Crohn's disease came from Omer and colleagues in 2007. It remains the most methodologically rigorous study on this topic, and it is the one most frequently cited by supplement proponents - often without the important caveats.

Study Design and Patient Population

Omer and colleagues conducted a double-blind, placebo-controlled study across five medical centers in Germany (1). They enrolled 40 Crohn's disease patients who were already on stable steroid doses (defined as a starting prednisone-equivalent dose). The patients were randomized to receive either a wormwood herbal blend or placebo for 10 weeks while their steroids were gradually tapered according to a fixed schedule (1).

A critical detail that often gets lost in popular summaries: the treatment was a herbal blend containing wormwood as the primary ingredient, not a pure Artemisia absinthium extract. This matters because attributing the results solely to wormwood is scientifically imprecise - other herbs in the blend may have contributed.

Dosage and Duration

Participants in the active group took 500 mg of the wormwood herbal blend three times daily (1,500 mg total per day) for 10 weeks (1). This is important context because the dose, formulation, and duration of any supplement study define the boundaries of what the evidence actually supports. A different product at a different dose for a different duration may produce entirely different results.

What the Results Showed

The wormwood group showed significantly greater reductions in both TNF-alpha levels and Crohn's Disease Activity Index (CDAI) scores compared with the placebo group (1). Patients receiving wormwood also reported improved quality-of-life scores on the Inflammatory Bowel Disease Questionnaire (IBDQ) and better mood scores on the Hamilton Depression Scale (1).

The study is frequently described as demonstrating a "steroid-sparing effect" - meaning that patients on wormwood were able to taper off steroids more successfully than those on placebo. This is a genuinely interesting result. However, the trial's small sample size (only 20 patients per arm), the use of a multi-herb blend rather than pure wormwood, and the absence of independent replication all place significant limits on how confidently we can apply these findings.

The 2010 TNF-Alpha and Mucosal Healing Trial

Three years later, a related research group published a second trial with an even more focused look at wormwood's effect on TNF-alpha and clinical outcomes in Crohn's disease.

Small Controlled Trial in 20 Patients

Krebs and colleagues enrolled 20 patients with active Crohn's disease, assigning 10 to receive dried powdered wormwood at 750 mg three times daily (2,250 mg total per day) in addition to their standard therapy, and 10 to continue standard therapy alone (2). The treatment period was 6 weeks - shorter than the 2007 trial and with an even smaller sample.

Biochemical and Clinical Outcomes

The results were striking in their magnitude. Average serum TNF-alpha in the wormwood group fell from 24.5 plus or minus 3.5 pg/mL at baseline to 8.0 plus or minus 2.5 pg/mL at week 6 - roughly a 67 percent reduction (2). The control group showed little change in TNF-alpha over the same period.

Clinically, CDAI scores in the wormwood group dropped from around 275 (indicating moderately active disease) to under 175 (the conventional cutoff for clinical remission), with symptom remission reported in 8 of 10 patients receiving wormwood versus 2 of 10 controls (2). The authors also reported improved Hamilton Depression Scale scores in the wormwood group, though they acknowledged the sample was far too small to draw firm conclusions about mood effects (2).

These are compelling numbers on paper. But a study of 10 versus 10 patients, without blinding and without a placebo control (the comparison was standard therapy alone), carries substantial risk of bias. We cannot be sure that patients and clinicians were not influenced by knowing which group each patient was in.

Safety: Thujone, Neurotoxicity, and Who Should Not Use Wormwood

For many of us in the Crohn's community, the instinct when hearing about a supplement with positive trial results is to wonder where to buy it. With wormwood, the safety discussion deserves as much attention as the efficacy data - possibly more.

What Thujone Does in the Body

Wormwood contains thujone, a naturally occurring compound that acts as a GABA-A receptor antagonist in the nervous system (4). GABA is the brain's main inhibitory neurotransmitter - the chemical that calms neural activity. When thujone blocks GABA receptors, the result can be overexcitation of the nervous system. At low doses, this may cause nothing noticeable. At high or prolonged doses, thujone can trigger convulsions, sleeplessness, restlessness, and, historically, the hallucinations associated with excessive absinthe consumption (4).

This is not a theoretical concern. Thujone toxicity is well documented in case reports, and it is the primary reason that wormwood is tightly regulated in many countries.

Regulatory Classification and Product Forms

The essential oil of wormwood concentrates thujone at levels far higher than the dried herb (4). The essential oil should never be taken internally - a point that is not always made clear on supplement-focused websites. The clinical trials in Crohn's disease used dried herb or low-thujone herbal blends at specific doses for short durations under medical supervision. That is a very different exposure from buying a bottle of wormwood essential oil and adding it to tea.

Regulatory bodies in the EU restrict thujone content in food and beverages, and many countries classify high-thujone wormwood products differently from low-thujone dried herb preparations. The Crohn's and Colitis Foundation reminds patients that dietary supplements in general do not require FDA approval before reaching store shelves, which means quality, potency, and thujone content can vary dramatically between products (5).

Contraindications and Drug Interactions

Wormwood is contraindicated in pregnancy, breastfeeding, young children, and people with severe liver or kidney disease or a history of seizures (4). Patients on antiepileptic medications should be especially cautious, given thujone's mechanism as a GABA-A antagonist.

For Crohn's patients specifically, the question of drug interactions is largely unanswered. There are no formal pharmacokinetic interaction studies between wormwood and biologics like infliximab (marketed as Remicade and various biosimilars), adalimumab, or ustekinumab. Similarly, interactions with immunomodulators such as azathioprine or methotrexate have not been studied. This does not mean interactions definitely occur - it means we genuinely do not know, which is its own kind of risk.

How Strong Is the Evidence, Really?

It is easy to get excited about wormwood when you read the trial headlines. A 67 percent drop in TNF-alpha sounds dramatic. Remission in 8 of 10 patients sounds transformative. But evidence strength depends on more than the numbers in a single paper.

What the 2023 IBD Natural Products Review Concluded

A comprehensive 2023 review published in the journal Life examined plant-derived natural products tested in IBD, and it acknowledged Artemisia absinthium as one of the few herbs with double-blind, randomized controlled trial evidence specifically in Crohn's disease (3). That is genuinely noteworthy - the vast majority of herbal supplements promoted for Crohn's have nothing close to this level of clinical testing.

What Is Still Missing

However, the total evidence base for wormwood in Crohn's disease consists of two small trials from the same research group, enrolling a combined total of approximately 60 patients (1, 2). No independent research team has replicated these findings in over a decade. No large multicenter trial has been conducted. No major gastroenterology society guideline - not the AGA, not ECCO, not the ACG - recommends wormwood as monotherapy or maintenance therapy for Crohn's disease.

Standardization is another unresolved problem. Wormwood products available to consumers vary widely in thujone content, the ratio of active sesquiterpene lactones, and overall quality control. The specific formulations used in the German trials may not match what is available at your local health food store or online retailer.

For those interested in the broader landscape of herbs and complementary approaches studied in Crohn's, our guides to turmeric for Crohn's disease and mastic gum for Crohn's disease cover other traditional remedies with varying levels of evidence. And for a wider view of complementary options, our overview of complementary therapies for Crohn's disease provides helpful context.

Talking to Your Care Team Before Trying Wormwood

If you are seriously considering wormwood after reading the trial data, the most important next step is a specific, practical conversation with your gastroenterologist - not a vague mention of "trying some herbal stuff."

Bring the Specifics

Show your GI doctor the exact product you are considering: the brand, the dose per capsule, the recommended daily intake, and any information available about thujone content. If the product label does not specify thujone levels, that itself is useful information - it tells you (and your doctor) that standardization is unclear. Ask whether your current liver function values and seizure history (if any) make wormwood a reasonable consideration or a clear no.

Ask specifically about potential interactions with your biologic, immunomodulator, or any ongoing steroid taper. Your doctor may also want to monitor liver function tests if you proceed, given the limited safety data for long-term use.

Never Replace Prescribed Therapy

The clinical trial evidence for wormwood, such as it is, tested the herb as an add-on to standard therapy - not as a replacement for biologics, immunomodulators, or any prescribed Crohn's medication (1, 2). Stopping a working biologic to try wormwood based on two pilot studies would be taking a risk that the current evidence does not support.

If your clinician advises against wormwood, ask what alternative complementary options they consider safer or better studied. The Crohn's and Colitis Foundation maintains a patient resource on complementary medicine that can serve as a starting point for that conversation (5).

Frequently Asked Questions

Is wormwood proven to treat Crohn's disease?

Not yet. Two small trials totaling about 60 patients reported lower TNF-alpha and improved symptoms, but no large confirmatory trial has been conducted and no gastroenterology society recommends wormwood as a Crohn's treatment (1, 2, 3). The results are preliminary and come from a single research group.

What dose of wormwood was used in the Crohn's trials?

The 2007 trial used 500 mg three times daily (1,500 mg/day) of a wormwood herbal blend for 10 weeks (1). The 2010 trial used 750 mg three times daily (2,250 mg/day) of dried powdered wormwood for 6 weeks (2). These doses were administered under medical supervision and may not reflect commercially available products.

Is wormwood safe to take with biologics like infliximab or adalimumab?

There are no formal drug interaction studies between wormwood and any biologic or immunomodulator used in Crohn's disease. This means we do not know whether interactions occur. Always discuss with your gastroenterologist before combining wormwood with any prescribed IBD therapy.

Can wormwood essential oil be taken internally for Crohn's?

No. Wormwood essential oil concentrates thujone at levels far higher than dried herb and poses a genuine risk of neurotoxicity (4). The Crohn's disease trials used dried herb or low-thujone herbal blends, never essential oil. Oral use of the essential oil is unsafe.

Who should absolutely avoid wormwood?

Wormwood is contraindicated in pregnancy, breastfeeding, young children, and people with severe liver or kidney disease or a history of seizures (4). Because thujone is a GABA-A receptor antagonist, anyone taking antiepileptic medications should be especially cautious. International regulations on wormwood products vary by country.

How is wormwood different from other herbal supplements for Crohn's?

Unlike most herbal supplements marketed for Crohn's, wormwood has been tested in two double-blind or controlled trials enrolling specifically diagnosed Crohn's disease patients (3). However, the evidence base is still very small. Other herbs like Boswellia serrata and turmeric have different mechanisms and different levels of evidence.

What should I ask my doctor about wormwood?

Bring the specific product (brand, dose, thujone content if listed) and ask whether it is safe given your current medications, liver function, and seizure history. Ask about monitoring - your doctor may want liver function tests. And ask whether they consider any complementary option better supported by evidence for your specific situation (5).

References

1. Omer B, Krebs S, Omer H, Noor TO. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: A double-blind placebo-controlled study. Phytomedicine, 2007;14(2-3):87-95. View on PubMed
2. Krebs S, Omer TN, Omer B. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease: A controlled clinical trial. Phytomedicine, 2010;17(5):305-9. View on PubMed
3. Davila MM, Papada E. The Role of Plant-Derived Natural Products in the Management of Inflammatory Bowel Disease: What Is the Clinical Evidence So Far? Life (Basel), 2023. Read study
4. Batiha GE, Olatunde A, El-Mleeh A, Hetta HF, et al. Bioactive Compounds, Pharmacological Actions, and Pharmacokinetics of Wormwood (Artemisia absinthium). Antibiotics (Basel), 2020. Read study
5. Crohn's and Colitis Foundation. Complementary Medicine. 2024. Read article